

Innoviva Investor Presentation April 12, 2017

SPECIAL NOTE REGARDING THIS PRESENTATION

ON MARCH 22, 2017, SARISSA CAPITAL MANAGEMENT LP ("<u>SARISSA</u>"), TOGETHER WITH THE OTHER PARTICIPANTS IN SARISSA'S PROXY SOLICITATION (THE "<u>PARTICIPANTS</u>"), FILED A DEFINITIVE PROXY STATEMENT AND ACCOMPANYING GOLD PROXY CARD WITH THE SECURITIES AND EXCHANGE COMMISSION (THE "<u>SEC</u>") TO BE USED TO SOLICIT PROXIES IN CONNECTION WITH THE 2017 ANNUAL MEETING OF SHAREHOLDERS OF INNOVIVA, INC. (THE "<u>COMPANY</u>"). SHAREHOLDERS ARE ADVISED TO READ THE DEFINITIVE PROXY STATEMENT AND OTHER DOCUMENTS RELATED TO THE SOLICITATION OF PROXIES FROM THE SHAREHOLDERS OF THE COMPANY BECAUSE THEY CONTAIN IMPORTANT INFORMATION, INCLUDING INFORMATION RELATING TO THE PARTICIPANTS. THE DEFINITIVE PROXY STATEMENT AND A FORM OF PROXY IS AVAILABLE TO SHAREHOLDERS OF THE COMPANY AT NO CHARGE AT THE SEC'S WEBSITE AT <u>WWW.SEC.GOV</u>. THE DEFINITIVE PROXY STATEMENT AND A FORM OF PROXY IS ALSO AVAILABLE BY CONTACTING SARISSA'S PROXY SOLICITOR, D.F. KING & CO., INC., BY TELEPHONE AT THE FOLLOWING NUMBERS: STOCKHOLDERS CALL TOLL-FREE: (800) 549–6746 AND BANKS AND BROKERAGE FIRMS CALL: (212) 269–5550, OR THROUGH THE INTERNET AT <u>WWW.DFKING.COM/INVA</u>.

This presentation includes information based on data found in filings with the SEC, independent industry publications and other sources. Although the Participants believe that the data is reliable, they do not guarantee the accuracy or completeness of this information and have not independently verified any such information. Many of the statements in this presentation reflect the Participants' subjective belief. Although they have reviewed and analyzed the information that has informed their opinions, they do not guarantee the accuracy of any such beliefs. They have not sought, nor have they received, permission from any third-party to include their information in this presentation.



Summary

 Sarissa believes that Innoviva's directors Barbara Duncan, Catherine J. Friedman, Patrick G. LePore, Paul A. Pepe, James L. Tyree and William H. Waltrip have breached their fiduciary duties by (1) overpaying their executives and (2) overpaying themselves

INNOVIVA DOES NOT MARKET OR SELL ANY DRUGS. IT JUST COLLECTS ROYALTY PAYMENTS. SO WHY IS INNOVIVA'S SPENDING AND COMPENSATION SO EXORBITANT?

IT IS TIME FOR INNOVIVA TO BE OPTIMIZED FOR SHAREHOLDERS



Biospecifics Technologies Corp. currently collects royalties on <u>1</u> drug... Total compensation of Principal Executive Officer in 2015 \rightarrow \$354K

Name And Principal Position	Year	Salary (\$) (2)	All Other Compensation (\$)	Total (\$)
Thomas Wegman President, Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer (1)	2015	350,000	3,607(4)	353,607
	2014	350,000(3)	3,325(4)	353,325
	2013	320,833(3)	2,828(4)	323,661

DEF 14A filed April 2016

Biospecifics Technologies collects royalties on its injectable collagenase, marketed as XIAFLEX[®] by Endo International plc. Biospecifics Technologies is developing the collagenase in additional indications and in first quarter 2017 expected to initiate a clinical trial in uterine fibroids



Enzon Pharmaceuticals currently collects royalties on <u>4</u> drugs... Total compensation of Principle Executive Officer in 2015 \rightarrow \$40K

DEF 14A filed May 2016			Ste all	0	Non-Equity	All Other	
Name and Principal Position	Year	Salary (\$) ⁽¹⁾	Stock Awards (\$)	Option Awards (\$)	Incentive Plan Compensation (\$)	Compensation (\$) ⁽²⁾	Total (\$)
George W. Hebard III	2015					40,250	40,250
Former Interim Principal Executive Officer, Interim Chief Operating Officer and Secretary	2014	_	_	_	-	64,708	64,708
Richard L. Feinstein Vice President - Finance and Chief Financial Officer	2015 2014			_	_	123,964 138,094	123,964 138,094

Enzon Pharmaceuticals, Inc. receives royalty revenues from existing licensing arrangements with other companies primarily related to sales of four marketed drug products, namely, PegIntron [®], Sylatron [®], Macugen [®] and CIMZIA [®]



Innoviva currently collects royalties on <u>2</u> drugs...

DEF 111 filed March 2016

Total compensation of CEO in 2015 \rightarrow \$3.6 million


DEF 14A meu	IVIdICI	12010						
Name and Principal Position	Year	Salary (\$)(1)	Bonus (\$)	Stock Awards (\$)(2)	Option Awards (\$)(2)	Non-Equity Incentive Plan Compensation (\$)(3)	All Other Compensation (\$)(4)	Total (\$)
(a)	(b)	(c)	(d)	(e)	(f)	(g)	(i)	(i)
Michael W.	2016	746,688	_	2,159,152	_	672,019	19,667	3,597,526
Aguiar								
President and	2015	721,438	_	2,314,256	_	516,206	9,000	3,560,900
Chief								
Executive Officer	2014	557,247	—	3,564,881	_	437,500	500	4,560,128

10x the amount paid at Biospecifics; **90x** the amount paid at Enzon

Innoviva's current business is focused on collecting royalties from two respiratory inhalers sold and marketed by GSK



We believe the directors of Innoviva are failing to uphold their fiduciary duties by paying the CEO excessive multiples of what CEOs at other companies that simply collect royalties are paid





Biospecifics Technologies Corp. currently collects royalties on <u>1</u> drug... Median compensation of directors in 2015 \rightarrow \$68K

Name	Fees Earned or Paid in Cash (\$) (1)	Option Awards (\$) (2)(3)	Total (\$)	
Dr. Paul Gitman(2)	65,000		65,000	
Michael Schamroth(2)	65,000		65,000	
Dr. Mark Wegman(2)	68,529 (4)		68,529 (4)	
Toby Wegman(2)	22,000		22,000	
George Gould (2)	68,377 (5)		68,377 (5)	
Dr. Jyrki Mattila (3)	44,966	42,182	87,148	
Ms. Jennifer Chao (3)	44,966	42,182	87,148	

DEF 14A filed April 2016

Biospecifics Technologies collects royalties on its injectable collagenase, marketed as XIAFLEX[®] by Endo International plc. Biospecifics Technologies is developing the collagenase in additional indications and in first quarter 2017 expected to initiate a clinical trial in uterine fibroids



Enzon Pharmaceuticals currently collects royalties on <u>4</u> drugs... Median compensation of directors in 2015 \rightarrow \$35K

DEF 14A filed May 2016	Fees Earned			
Name	or Paid in Cash (\$)	Stock Awards (\$) ⁽¹⁾	Option Awards (\$) ⁽²⁾	Total
Jonathan Christodoro	40,000	_	_	40,000
Odysseas Kostas	35,000	_	—	35,000
Jennifer I. McNealey	35,000	_	_	35,000

Enzon Pharmaceuticals, Inc. receives royalty revenues from existing licensing arrangements with other companies primarily related to sales of four marketed drug products, namely, PegIntron [®], Sylatron [®], Macugen [®] and CIMZIA [®]



Innoviva currently collects royalties on <u>2</u> drugs...

Median compensation of directors in 2015 \rightarrow \$330K

DEF 14A filed March 2016		Fees Earned or Paid in Cash	Stock Awards	Total
	Name	(\$)(1)	(\$)(2)(3)	(\$)
	(a)	(b)	(C)	(h)
Catherine J. Friedman		70,000	249,984	319,984
Terrence C. Keamey		67,500	249,984	317,484
Paul A. Pepe		80,000	249,984	329,984
James L. Tyree		80,000	249,984	329,984
William H. Waltrip		112,500	249,984	362,484

~5x the amount paid at Biospecifics;
~9x the amount paid at Enzon

Innoviva's current business is focused on collecting royalties from two respiratory inhalers sold and marketed by GSK




Even more remarkable... in 2015 the median compensation of directors at Innoviva was >\$100K higher than Theravance Biopharma, the company that it spun off in 2014 that has a real operating business!

Innoviva

	Total compensation (2015)
Catherine J. Friedman	319,984
Terrence C. Kearney	317,484
Paul A. Pepe	329,984
James L. Tyree	329,984
William H. Waltrip	362,484
MEDIAN	329,984

Theravance Biopharma, Inc.				
Non-executive director	Total compensation (2015)			
Eran Broshy	163,641			
Henrietta H. Fore	193,293			
Robert V. Gunderson, Jr.	196,577			
Burton G. Malkiel, Ph.D.	233,125			
Dean J. Mitchell	213,577			
Susan Molineaux, Ph.D	352,143			
Donal O'Connor	162,189			
Peter S. Ringrose	220,757			
George M. Whitesides, Ph.D.	205,165			
William D. Young	241,580			
MEDIAN	209,371			

Theravance Biopharma has a real operating business – marketed product, salesforce and extensive R&D pipeline – and yet lower director compensation than Innoviva! We believe the directors at Innoviva are failing to uphold their fiduciary duties by paying themselves multiples of what directors at other companies that simply collect royalties are paid





Note, comparing compensation at Innoviva to other companies of similar size by revenue or market cap is misguided

- Unlike other companies in its peer group by size:
 Innoviva does not sell or market drugs!
 - Innoviva does not engage in any real R&D!

We believe these are critical points to understanding Innoviva's compensation. In this context, compensation at Innoviva can be appreciated as especially egregious, a true extreme! In light of Innoviva's excessive spending, including egregious compensation of management and directors

 Sarissa is gravely concerned that Innoviva will squander future royalty revenues on M&A (management has already expressed a desire to "build over time a recurring revenue business")¹, additional overcompensation of management and directors and other misguided spending



Sarissa is particularly concerned that Innoviva will waste shareholder money on imprudent acquisitions

- Sarissa believes shareholders should not be confident that the current board and management team will make the right capital allocation decisions
- Sarissa is fearful that any imprudent acquisitions will irreversibly alter the strategic position of the company and thereby irreparably damage shareholder value
- Innoviva should clarify to shareholders its intentions regarding acquisitions



INNOVIVA DOES NOT MARKET OR SELL ANY DRUGS. IT JUST COLLECTS ROYALTY PAYMENTS. SO WHY IS INNOVIVA'S SPENDING AND COMPENSATION SO EXORBITANT?

IT IS TIME FOR INNOVIVA TO BE OPTIMIZED FOR SHAREHOLDERS



ISS, Glass Lewis and Egan-Jones all recommend that Innoviva shareholders vote on Sarissa's GOLD PROXY CARD

- ISS and Egan-Jones recommend all three Sarissa nominees and Glass Lewis recommends two Sarissa nominees
- All three recommend shareholders vote AGAINST Innoviva's executive compensation
- All three recommend shareholders NOT VOTE ON MANAGEMENT'S WHITE CARD



We urge you to VOTE THE GOLD PROXY CARD

- Time is of the essence. We urge you to VOTE THE GOLD PROXY CARD to help us fix the problems at Innoviva. If you want to follow the recommendations of ISS, Glass Lewis and Egan-Jones and vote for Sarissa nominees YOU MUST VOTE ON THE GOLD CARD AND YOU CANNOT VOTE THE WHITE CARD. Returning a white card, even if you withhold on Innoviva's nominees, will not be a vote for the Sarissa nominees, and it would revoke any vote you previously submitted on the GOLD CARD. PLEASE VOTE NOW by signing, dating and returning the GOLD proxy card or by voting by phone or internet.
- If you have any questions regarding your GOLD proxy card or need assistance in voting, please contact our proxy solicitor:

D.F. KING & CO., INC. STOCKHOLDERS CALL TOLL-FREE: (800) 549–6746 BANKS AND BROKERAGE FIRMS CALL: (212) 269–5550 WWW.DFKING.COM/INVA



To be continued...

